Seeking Alpha

Canaccord, Wedbush initiate bullish coverage on Enzymotec

  • Canaccord starts recently public Enzymotec (ENZY +1%) at Buy.
  • Analyst Scott Van Winkle says the company "is well positioned to drive sustained growth in the highly attractive nutrition market, translating into strong sales, margin, and earnings momentum."
  • Price target is $24, representing a 35% upside from Monday's close.
  • Also picking up coverage is Wedbush, where analyst Rommel Dionisio starts the shares at Outperform with a $21 price target. "With its proprietary technology in lipids and expanding global distribution platform, ENZY will continue to gain market share within three fast-growing industry segments of nutritional foods and supplements: krill oil; infant nutrition; and medical foods,"  Dionisio says.
  • Wedbush note is here
From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs